NASDAQ:NXTCNextCure Stock Price, Forecast & News

NextCure's stock was trading at $38.22 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NXTC shares have decreased by 74.6% and is now trading at $9.70.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for NextCure.

NextCure is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for NextCure.

NextCure Inc (NASDAQ:NXTC) posted its quarterly earnings data on Thursday, May, 7th. The company reported $0.33 earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.77. The business earned $22.38 million during the quarter, compared to analyst estimates of $1.30 million. NextCure had a negative net margin of 65.22% and a negative return on equity of 7.12%.
View NextCure's earnings history.

9 brokers have issued 1 year price objectives for NextCure's shares. Their forecasts range from $11.00 to $87.00. On average, they expect NextCure's stock price to reach $32.70 in the next twelve months. This suggests a possible upside of 237.1% from the stock's current price.
View analysts' price targets for NextCure.

News headlines about NXTC stock have been trending negative on Thursday, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NextCure earned a news impact score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about NextCure.

Some companies that are related to NextCure include VBI Vaccines (VBIV), Retrophin (RTRX), Arcus Biosciences (RCUS), Amphastar Pharmaceuticals (AMPH), Phathom Pharmaceuticals (PHAT), Enanta Pharmaceuticals (ENTA), I-Mab (ARQT), Phibro Animal Health (PAHC), BioXcel Therapeutics (BTAI), DiaMedica Therapeutics (DMCAF), Athenex (ATNX), Generation Bio (GBIO), Aimmune Therapeutics (AIMT), Stoke Therapeutics (STOK) and Gossamer Bio (GOSS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include Amgen (AMGN), Alibaba Group (BABA), CVS Health (CVS), Dicerna Pharmaceuticals (DRNA), UnitedHealth Group (UNH), Honeywell International (HON), Johnson & Johnson (JNJ), NVIDIA (NVDA), AT&T (T) and Arena Pharmaceuticals (ARNA).

(NXTC) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

NextCure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Matthews International Capital Management LLC (0.92%), Vident Investment Advisory LLC (0.20%), Vident Investment Advisory LLC (0.20%), Asymmetry Capital Management L.P. (0.18%), SG Americas Securities LLC (0.12%) and Swiss National Bank (0.10%). Company insiders that own NextCure stock include Sofinnova Venture Partners Ix,, Stella Xu and X LP Canaan.
View institutional ownership trends for NextCure.

NXTC stock was purchased by a variety of institutional investors in the last quarter, including Matthews International Capital Management LLC, Asymmetry Capital Management L.P., SG Americas Securities LLC, Swiss National Bank, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Bessemer Group Inc., and Virtus ETF Advisers LLC. Company insiders that have bought NextCure stock in the last two years include Sofinnova Venture Partners Ix,, Stella Xu, and X LP Canaan.
View insider buying and selling activity for NextCure.

Shares of NXTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NXTC stock can currently be purchased for approximately $9.70.

NextCure has a market capitalization of $266.94 million and generates $6.35 million in revenue each year. The company earns $-33,740,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis.

The official website for NextCure is www.nextcure.com.

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The company can be reached via phone at 240-399-4900 or via email at [email protected]